Pulmonx (LUNG) Return on Capital Employed (2020 - 2025)
Pulmonx's (LUNG) quarterly Return on Capital Employed came in at 47.7% in Q3 2025, down 934.0% year-on-year from 5.72% in Q3 2024, and down 6.05% on a QoQ basis from 44.99% in Q2 2025.
Pulmonx (LUNG) Return on Capital Employed (2020 - 2025) Analysis & Trends
Pulmonx (LUNG) has 6 years of Return on Capital Employed data on file, last reported at 47.7% in Q3 2025.
- On a quarterly basis, Return on Capital Employed fell 934.0% year-over-year to 47.7% in Q3 2025; TTM through Sep 2025 was 47.7%, a 934.0% decrease from a year earlier, with the FY2024 full-year figure at 39.56%, down 146.0% from the prior year.
- Return on Capital Employed for Q3 2025 stood at 47.7%, down from 44.99% in the prior quarter.
- Over the last five years, Return on Capital Employed for LUNG reached as high as 15.77% in Q1 2021 and fell as low as 47.7% in Q3 2025.
- Historically, Return on Capital Employed has averaged 32.92% across 5 years, with a median of 34.56% in 2023.
- Across the five-year window, Return on Capital Employed fell 30 bps in 2021 and plunged 1151 bps in 2022, its largest moves.
- Year by year, Return on Capital Employed stood at 21.17% in 2021, then tumbled by 54 bps to 32.68% in 2022, then fell by 20 bps to 39.14% in 2023, then decreased by 5 bps to 41.02% in 2024, then retreated by 16 bps to 47.7% in 2025.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 47.7% in Q3 2025, 44.99% in Q2 2025, and 43.79% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pulmonx | 49.94 Mn | -19.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -47.70% |
| Jun 30, 2025 | -44.99% |
| Mar 31, 2025 | -43.79% |
| Dec 31, 2024 | -41.02% |
| Sep 30, 2024 | -38.37% |
| Jun 30, 2024 | -38.90% |
| Mar 31, 2024 | -40.08% |
| Dec 31, 2023 | -39.14% |
| Sep 30, 2023 | -37.16% |
| Jun 30, 2023 | -34.56% |
| Mar 31, 2023 | -32.91% |
| Dec 31, 2022 | -32.68% |
| Sep 30, 2022 | -30.35% |
| Jun 30, 2022 | -26.45% |
| Mar 31, 2022 | -23.89% |
| Dec 31, 2021 | -21.17% |
| Sep 30, 2021 | -19.63% |
| Jun 30, 2021 | -16.91% |
| Mar 31, 2021 | -15.77% |
| Dec 31, 2020 | -20.87% |